Cat. No.: DAB-0012389
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Monkey |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro301 of human PAPSS2 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | PAPSS2 |
| UniProt No. | O95340 |
| Gene ID | 9060 |
| Gene Description | PAPSS2 is a bifunctional enzyme with both ATP sulfurylase and APS kinase activity, which mediates two reactions to generate 3'-Phosphoadenosine-5'-phosphosulfate, a critical intermediate in the sulfate activation pathway. PAPS is the sulfate donor co-substrate for all sulfotransferase enzymes and is required to catalyze the sulfate conjugation of many endogenous and exogenous compounds. Mutations in PAPSS2 lead to an autosomal recessive form of spondyloepimetaphyseal dysplasia in humans, whereas mutant mice lacking PAPSS2 activity demonstrate defective postnatal skeletal development leading to premature joint degeneration and brachymorphism. In conjunction with SULT1E1, PAPSS2 and its paralogue PAPSS1 are responsible for sulfation and subsequent inactivation of estrogen in target tissues. Expression levels of PAPSS2 were found to be significantly higher in tumorous breast and endometrial tissues than in adjacent normal tissues, suggesting that targeting PAPSS2 could be an important approach for estrogen-dependent cancers. Additionally, PAPSS2 provides the universal sulfate donor PAPS to SULT2A1, which is responsible for sulfation of the crucial androgen precursor dehydroepiandrosterone. TGF-β signaling has been shown to regulate the expression of PAPSS2 via stabilization of SOX9 protein in mouse articular cartilage and bovine chondrocytes. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
